Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07471490Enrolling By Invitation

Specimen and Data Collection for a Novel Biomarker Combination for the Differential Diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome.

Role: lead

NCT05041595Enrolling By Invitation

Lyme Disease Diagnostic Assay - Collection of Whole Blood

Role: lead

NCT05168917Not ApplicableCompleted

EURECA (EUropeanRElapseCAlprotectin) Study

Role: lead

NCT03060746Completed

Helicobacter Pylori Sample Collection Protocol Pre Therapy Subjects

Role: lead

NCT03060733Completed

Helicobacter Pylori Sample Collection Protocol Post Therapy Subjects

Role: lead

NCT03143517Completed

Fecal Calprotectin Collection Protocol

Role: lead

All 6 trials loaded